Hollow-fibre infection model: adaptations for the culture and assessment of fastidious organisms

References

1. Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 2013; 65:1053–1090 [View Article] [PubMed]
   [Google Scholar]
2. Cadwell JJ. The hollow fiber bioreactor and cell co-cultivation. Fiber Cell Systems 2012
   [Google Scholar]
3. Toutain PL, Pelligand L, Lees P, Bousquet-Mélou A, Ferran AA et al. The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: recent advances and critical appraisal. J Vet Pharmacol Ther 2021; 44:172–200 [View Article] [PubMed]
   [Google Scholar]
4. Sadouki Z, McHugh TD, Aarnoutse R, Ortiz Canseco J, Darlow C et al. Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. J Antimicrob Chemother 2021; 76:2252–2259 [View Article] [PubMed]
   [Google Scholar]
5. Cadwell J. The hollow fiber infection model: principles and practice. Adv Antibiotics Antibodies 2015; 1:
   [Google Scholar]
6. Cadwell J. The hollow fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics. Adv Pharmacoepidem Drug Safety 2012; 1:2167–1052 [View Article]
   [Google Scholar]
7. Schaumann R, Goldstein EJ, Forberg J, Rodloff AC. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 2005; 54:749–753 [View Article] [PubMed]
   [Google Scholar]
8. Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH et al. Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans.. Antimicrob Agents Chemother 2019; 63:02307–02318 [View Article] [PubMed]
   [Google Scholar]
9. European Medicines Agency Qualification Opinion. In-Vitro Hollow Fiber System Model of Tuberculosis (HSF-TB) European Medicines Agency Canary Wharf; 2015
   [Google Scholar]
10. European Committee on antimicrobial susceptibility testing Media preparation for EUCAST disk diffusion testing and for determination of MIC values by the broth microdilution method. European Society of Clinical Microbiology and Infectious Diseases; 2022 https://www.eucast.org/ast_of_bacteria/media_preparation
11. CLSI Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. In CLSI Guideline M45, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016
    [Google Scholar]
12. Cartwright CP, Stock F, Gill VJ. Improved enrichment broth for cultivation of fastidious organisms. J Clin Microbiol 1994; 32:1825–1826 [View Article] [PubMed]
    [Google Scholar]
13. Konze SA, Abraham W-R, Goethe E, Surges E, Kuypers MMM et al. Link between heterotrophic carbon fixation and virulence in the porcine lung pathogen Actinobacillus pleuropneumoniae. Infect Immun 2019; 87:00768 [View Article] [PubMed]
    [Google Scholar]
14. Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F et al. Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model. Front Pharmacol 2021; 12:682135 [View Article] [PubMed]
    [Google Scholar]
15. Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D et al. Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model. Front Pharmacol 2022; 13:874176 [View Article] [PubMed]
    [Google Scholar]
16. Jacobsson S, Golparian D, Oxelbark J, Wicha WW, da Costa RMA et al. Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections. Front Pharmacol 2022; 13:1035841 [View Article] [PubMed]
    [Google Scholar]
17. VanScoy BD, Scangarella-Oman NE, Fikes S, Min S, Huang J et al. Relationship between gepotidacin exposure and prevention of on-therapy resistance amplification in a Neisseria gonorrhoeae hollow-fiber in vitro infection model. Antimicrob Agents Chemother 2020; 64:00521–20 [View Article] [PubMed]
    [Google Scholar]
18. Embrechts J, Sedlák L, Hlavizna I, Heřmanský P, Ćechová I et al. The influence of the galenic form on pharmacokinetics of florfenicol after intramuscular administration in pigs. J Vet Pharmacol Ther 2013; 36:92–94 [View Article] [PubMed]
    [Google Scholar]
19. Voorspoels J, D’Haese E, De Craene BA, Vervaet C, De Riemaecker D et al. Pharmacokinetics of florfenicol after treatment of pigs with single oral or intramuscular doses or with medicated feed for three days. Vet Rec 1999; 145:397–399 [View Article] [PubMed]
    [Google Scholar]
20. Jorgensen J, Maher L, Howell A. Use of Haemophilus test medium for broth microdilution antimicrobial susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol 1990; 28:430–434 [View Article] [PubMed]
    [Google Scholar]